rhCollagen product
Collage is a solution of recombinant human collagen type I at a concentration of 3 mg/ml in hydrochloric acid.

CollPlant is a regenerative medicine company with products based on recombinant human collagen, such as the Collink.3D bioink platform.
collplant.comCrawled Nov 14, 2026
Collage is a solution of recombinant human collagen type I at a concentration of 3 mg/ml in hydrochloric acid.
The page discusses tendon injury treatments, highlighting the use of autologous platelet-rich plasma (PRP) for tendinopathy.
3D bioprinting combines living cells and biomaterials to create tissue-like constructs for research and drug screening.
Collink.3D is a lyophilized recombinant human collagen bioink for 3D bioprinting, available in 50 and 90 variants.
Collagen is a key component for tissue regeneration, providing structural support and biological signals.
The page lists academic publications on magnetic resonance imaging, collagen injections for lateral epicondylitis, and plant-derived recombinant human collagen in aesthetic medicine.
The page features media coverage, including videos on photocurable dermal filler, bioprinting, and presentations by Prof. Oded Shoseyov and Dr. Martine Rothblatt.
The page highlights presentations on photocurable recombinant human collagen for soft tissue correction and bioprinting applications at medical congresses.
CollPlant describes its workplace as a collaborative community focused on advancing regenerative medicine.
CollPlant uses plant-based technology to produce recombinant human collagen for medical solutions, combining human and environmental benefits.
CollPlant develops technologies and products for tissue regeneration and organ manufacturing using plant-based recombinant human collagen.
The page provides contact details for CollPlant’s rhCollagen technology and solutions.
CollPlant seeks partnerships with companies and institutions in regenerative medicine and aesthetics.
CollPlant develops technologies for regenerative medicine, medical aesthetics, and organ manufacturing.
CollPlant Biotechnologies Ltd. transitions its ordinary shares to Nasdaq under the new ticker symbol **OPHI**, replacing its previous listing. The change takes effect at the start of trading on **November 13, 2026**, marking a shift in its market presence.
LightSolver Ltd., a subsidiary of CollPlant Biotechnologies, will showcase its **Laser Processing Unit (LPU)**, an all-optical computer, in its first public demonstration at the **SC26 conference**. The LPU leverages pure photonic computing, distinguishing it from traditional electronic processors. The event marks a key milestone for LightSolver’s development in high-performance, energy-efficient computing solutions.
LightSolver Ltd. receives a ~$1.8 million grant from Israel’s Innovation Authority to further develop its Laser Processing Unit (LPU), an all-optical, laser-based computing platform. The funding supports ongoing research into this alternative computing architecture, which leverages light instead of traditional electronics. The grant highlights growing investment in optical computing technologies.
CollPlant Biotechnologies Ltd. proposes renaming to **OptiPhi Computing Ltd.** to reflect its shift into computing with light. The change requires shareholder approval and regulatory clearance. The company currently trades on Nasdaq under the ticker **CLGN**.
CollPlant secures a $3.7 million private placement to fund operations. The proceeds, before fees, will support the company’s growth and development initiatives. The placement highlights investor confidence in CollPlant’s business strategy.
CollPlant Biotechnologies acquires LightSolver, an Israeli deep-tech firm specializing in photonic computing using laser-based systems. The move expands CollPlant’s portfolio into a novel computing paradigm. LightSolver’s technology represents a departure from traditional electronic computing approaches.